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Rationale and Design: The accuracy of a prospective histopatho-
logic diagnosis of rejection and recurrent hepatitis C (HCY) was de-
tennined in 48 HCY RNA-positive liver allograft recipients enrolled 
in an "immunosuppression minimization protocol" between July 29, 
200 I and January 24, 2003. Prospective entry of all pertinent treat-
ment. laboratory, and histopathology results into an electronic data-
base enabled a retrospective analysis of the accuracy of histopatho-
logic diagnoses and the pathophysiologic relationship between recur-
rent HCY and rejection. 
Results: Time to first onset of acute rejection (AR) (mean, 107 days; 
median, 83 days; range, 7-329 days) overlapped with the time to first 
onset of recurrent HCY (mean, 115 days; median, 123 days; range, 
22-315 days), making distinction between the two difficult. AR and 
chronic rejection (CR) with and without co-existent HCY showed 
overlapping but significantly different liver injury test profiles. One 
major and two minor errors occurred (positive predictive values for 
AR = 91 %; recurrent HCY = 100%); all involved an overdiagnosis of 
AR in the context of recurrent HCY. Retrospective analysis of the 
mistakes showed that major errors can be avoided altogether and the 
impact of unavoidable minor errors can be minimized by strict adher-
ence to specific histopathologic criteria, close clinicopathologic cor-
relation including examination ofHCY RNA levels, and a conserva-
tive approach to the use of additional immunosuppression. In addi-
tion, histopathologic diagnoses of moderate and severe AR and CR 
were associated with relatively low Hey RN A levels, whereas relatively 
high HCY RNA levels were associated with a histopathologic diagnosis 
of hepatitis alone, particularly the cholestatic variant of HCY. 
Conclusions: Liver allograft biopsy interpretation can rapidly and 
accurately distinguish between recurrent HCY and AR/CR. In addi-
tion, the histopathologic observations suggest that the immune 
mechanism responsible for HCY clearance overlap with those leading 
to significant rejection. 
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Hepatitis C virus (HCY)-induced cirrhosis is the leading 
indication for liver transplantation throughout the 
world.32 Unfortunately, reinfection is nearly universal and rc-
current disease occurs in a majority of recipients. HCY repli-
cation can be detected in the RNA-positive recipients within 
days after transplantation, 27 Allograft dysfunction can occur as 
early as 1 week following transplantation in patients with high 
viral loads before transplantation,6 but the majority of HCY-
positive recipients usually first show signs of recurrent disease 
between 2 and 3 months, 1 t,31 
Distinguishing among recurrent viral hepatitis and AR 
and CR and other causes of allograft dysfunction is based pri-
marily on liver biopsy evaluation, Guidelines to rccognize in-
dividual syndromes were proposed more than a decade 
ago, t3,16 but experience has shown the distinction to be prob-
lematic. I ,19,25 
Steatosis is an early nonspecific finding in recurrent 
HCy5; spotty hepatocyte necrosis, lobular disarray, and 
Kupffer's cell hypertrophy are more reliable features that spe-
cifically point toward recurrent HCY as the cause of allograft 
injury.31,33 Later in the course of recurrent HCY, predomi-
nantly mononuclear portal inflammation with variable inter-
face activity and low-grade bile duct damage signal the transi-
tion from acute to chronic hepatitis. Chronic HCY is charac-
terized by mononuclear portal inflammation that is frequently 
arranged into nodular aggregates and mild bile duct damage 
that is neither as severe nor as widespread as is seen in acute 
rejection (AR) or chronic rejection (CR)31 Interface activity, 
including a type II ductular reaction, is also morc common in 
hepatitis than in rejection. Retrospective analysis of case ma-
terial to determine whether specific histopathologic criteria are 
useful in distinguishing among recurrent HCY and other 
causes of allograft dysfunction is fraught with pitfalls. 
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The Electronic Data Interface for Transplantation 
(EDIT) 15 software simultaneously creates an information por-
tal for patient management and populates a research database. 
Real-time entry of all pertinent treatment, laboratory, and his-
topathology data into this software has enabled us to accom-
plish our primary goal. This objective was to prospectively and 
rigorously test our ability to distinguish among recurrent HCV, 
rejection, and other various causes of liver allograft dysfunc-
tion in HCV RNA-positive recipients enrolled in a recent "im-
munosuppression minimization protocol.,,36 A secondary goal 
was to retrospectively analyze errors and determine how they 
might be avoided. 
The treatment protocol used in this patient population is 
based on the concept that alloantigen migration to the central 
lymphoid tissues of the recipient early after transplantation is 
an important event that simultaneously triggers rejection and 
tolerogenic immune responses. 35- 37 Pretransplant immuno-
depletion with anti-leukocyte antibodies is used to rein in the 
expected early alloresponse into a manageable range. This is 
combined with minimal posttransplantation monotherapy im-
munosuppression in an attempt to facilitate activation-induced 
apoptosis of donor-reactive lymphocytes. 36 A final goal of this 
study was to determine whether histopathologic observations 
in this unique patient population shed any insight into our con-
ceptual understanding ofHCV pathogenesis in the allografted 
liver. 
MATERIALS AND METHODS 
Patient Population and Pathology Workflow 
All primary liver allograft recipients with documented 
HCV infection (RNA positive by PCR) enrolled in the protocol 
between July 29,2001 and January 24,2003 were initially in-
cluded in this study (n = 53). Five patients either died within 1 
week of transplantation or did not undergo any posttransplan-
tation biopsies and were removed from the study. This left a 
total of 48 patients for analyses. The remaining patients were 
followed until March 31, 2003. Rationale for the treatment 
protocol is reported by Starzl et al.36 
Briefly, all liver allograft recipients were treatcd imme-
diately before transplantation with either broadly reactive rab-
bit anti-thymocyte globulin (Thymoglobulin; Sangstat, Menlo 
Park, CA; n = 25) or Alemtuzumab (Campath IH; n = 22) and 
simultaneously with 1 to 2 g methylprednisolone to concomi-
tantly prevent cytokine reactions.36 One patient inadvertently 
missed pretreatment. After transplantation patients were 
treated with tacrolimus monotherapy with the goal of achiev-
ing target trough levels of 10 ng/mL. Any additional immuno-
suppression, such as steroids or other agents, was added only 
temporarily to control biopsy-proven rejection. Beginning at 4 
months after transplantation, patients that had been on tacroli-
mus mono therapy for the preceding 60 days were considered 
for weaning. 36 After obtaining a protocol biopsy that was re-
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jection-free, twice daily tacrolimus doses were consolidated to 
once daily doses for a few weeks. In the continued absence of 
rejection, baseline immunosuppressive therapy was further 
weaned by spacing doses to every other day and subsequently 
to longer intervals.36 During immunosuppression weaning, 
unacceptable elevations of liver injury tests were investigated 
by liver allograft biopsies and other tests when appropriate. 
Mostly all biopsies were processed on a "STAT" basis with 
interpretation occurring on the same day the biopsy was ob-
tained. 
Experienced transplant pathologists (A.lD., M.A.N., 
P.R., or T.W.) initially reviewed all liver allograft biop-
sies. Each biopsy was evaluated according to a protocol 15 that 
listed 31 histologic findings for scoring (http://tpis.upmc. 
edultpis/schema! AlloLiver.html). Consultation among the pa-
thologists in difficult cases was routine at the time of signout. 
All biopsies were reviewed a second time immediately before 
a weekly clinicopathologic conference, when the free text di-
agnosis assigned by the primary pathologist was converted 
into "coded" diagnosis(es) by a single pathologist (A.1.D.) 
who re-reviewed the slides. 15 The diagnoses were also ranked 
in perceived order of importance with the most important listed 
first and discussed during the conference. Since all difficult 
cases were also discussed among the pathologists at the time of 
signout, there was only one instance of a significant disagree-
ment between the signout diagnosis and coded diagnosis, 
which did not impact the results ofthis study. 
Histopathologic Criteria for the Distinction 
Between Recurrent HCV and AR and CR and 
Assessment of Follow-up 
The criteria used to distinguish between AR and recur-
rent HCV were based on those originally developed for 
HBV. 13•16 Specifically, mild AR was diagnosed when either of 
the following conditions was met: I) portal inflammation with 
inflammatory bile duct damage involving 250% of the bile 
ducts; or 2) mononuclear peri venular inflammation involving 
250% of the terminal hepatic venules, associated with hepa-
tocyte necrosis and/or dropout. These criteria for mild AR re-
quire more extensive tissue injury than listed for the Banff cri-
teria3 in allografts not otherwise affected by a coexistent dis-
ease. Slightly more extensive tissue injury than usually seen in 
allografts without coexistent disease was also required for a 
diagnosis of moderate and severe AR, but the Banff criteria did 
not have to be adjusted. 
In general, a biopsy was considered adequate when it 
contained six or more portal tracts and four or more terminal 
hepatic venules. Early and late CR was diagnosed using the 
Banff criteria. 12 Recurrent HCV was diagnosed when lobular 
or interface necro-inflammatory activity was more prevalent 
and prominent than bile duct inflammation and damage. 
Patient outcome was used to gauge the accuracy of the 
prospectively entered histopathologic diagnoses. AR treat-
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ment consisted of bolus steroid therapy. If unsuccessful, daily 
tacrolimus therapy was re-instituted and other agents were 
added. For the purpose of this study, the diagnosis of AR was 
considered correct if peak liver injury test abnormalities at the 
time of diagnosis showed a sustained improvement of at least 
50% during the first week after additional immunosuppressive 
therapy. Liver injury tests eventually normalized with in-
creased immunosuppression in all of the patients with AR 
alone. 
Return to daily tacrolimus therapy until whole blood lev-
els registered at least 10 nglmL was used to treat CR; this was 
supplemented in some cases by simultaneous administration of 
other agents. A diagnosis of early CR was considered correct if 
there was a sustained decrease of 50% or more in total serum 
bilirubin therapy during the 2 months following treatment. 
Liver injury test eventually returned to normal or near-normal 
levels in all of the patients with early CR alone. 
Recurrent hepatitis C was treated either by no change in 
immunosuppression therapy or weaning of immunosuppres-
sion in patients more than 4 months after transplantation. This 
was supplemented by interferon-a (INTRON A or PEG-
INTRON; Schering, Kenilworth, NJ) and/or ribavirin 
(REBETROL; Schering) in patients that agreed to treatment 
and were able to tolerate the side effects. A diagnosis of recur-
rent HCV was considered correct if there was either no wors-
ening of liver injury tests for at least 2 weeks following the 
decision not to augment immunosuppression and/or introduce 
anti-viral therapy. However, most patients specifically treated 
for HCV with decreased immunosuppression and anti-viral 
therapy showed noticeable improvement. 
EDIT 
The EDIT software used to collect data for this study was 
designed and developed specifically for the Thomas E. Starzl 
Transplantation Institute at UPMC and described earlier in 
greater detail. 15 
Data Handling and Statistical Analysis 
Pertinent data from EDIT were first rendered anony-
mous by stripping it of unique patient identifiers, according to 
the exempt institutional review board-approved protocol 
(IRB#020 177). The cohort was described using estimates of 
central tendency (means, medians) and spread (standard devia-
tion, range) for continuous data and frequencies and percent-
ages for categorical data. Groups were compared using the i 
test for differences in proportions (categorical data) and the 
Wilcoxon Rank Sum test (continuous data). To identify poten-
tial predictors of AR and CR, Cox regression models were con-
structed. Time-dependent covariates were used when appro-
priate. For comparison ofliver injury tests, only those labora-
tory values that were obtained within -2 to 0 days prior to 
biopsy were eligible. However, the time range for eligible 
laboratory results was increased from -14 to 0 days for biop-
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sies showing CR because of the slower changes in liver injury 
tests associated with this diagnosis. All analyses were per-
formed using Statistical Analysis System (version 8.2). 
RESULTS 
Patient Characteristics and Graft and 
Patient Survival 
Donor and recipient age, sex, race, and viral genotype (if 
available) are shown in Table 1. Coexistent diseases compli-
cating HCV-induced cirrhosis are shown in Table 2. The mean 
and median follow-up for this group of patients was 292 and 
TABLE 1. Donor and Recipient Characteristics, Follow-up 
Period, and HeV Genotypes in Study Population 
Study Group 
(N = 48) 
Variable N [Column %J 
Gender 
Male 35 72.9% 
Female 13 27.1% 
Donor gender 
Male 29 60.4% 
Female 19 39.6% 
Race 
White 45 93.8% 
Black 0 0.0% 
Other 3 6.3% 
Donor race 
White 42 87.5% 
Black 5 10.4% 
Other 2.1% 
Age (yr) 
Mean (SO) 52.3 (8.3) 
Median 50.8 
Range 36.1-70.6 
Donor age (yr) 
Mean (SD) 47.6 (14.6) 
Median 50.7 
Range 13.7-78.4 
Follow-up (days) 
Mean (SO) 292.0 (172.7) 
Median 240.0 
Range 10--650 
Genotype 
la 16 33.3% 
Ib 8 16.7% 
3a 2 4.2% 
Other 7 14.6% 
Missing 15 31.3% 
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TABLE 2. Coexistent Diseases in Patients Who Underwent 
Liver Transplantation Primarily for HCV-Induced Cirrhosis 
None 
Coexistent 
Disease 1 
Hepatocellular carcinoma 
Alcoholic liver disease 
Alcoholic liver disease 
Chronic HBV 
Metabolic disease 
Total 
Coexistent 
Disease 2 
Hepatocellular carcinoma 
No. of 
Recipients 
28 
II 
5 
I 
2 
48 
240 days, respectively, with a range of 10 to 650 days. Patient 
survivals at 1,3, and 6 months and I year after transplantation 
were 98%, 94%, 85%, and 80%, respectively; graft survivals 
for the same intervals were 94%, 90%, 83%, and 78%. There 
were eight deaths and nine graft failures. The causes of death 
included liver allograft failure from primary dysfunction (n = 
3) complicated by myocardial infarction (n = I), cerebral an-
oxia (n = I), or multiorgan failure (n = 1). Three patients died 
with functioning allografts from an intracranial bleed (n = I), 
sepsis (n = I), and a motor vehicle accident (n = 1). Two other 
patients died because of liver allograft failure secondary to re-
current cholestatic HCV (n = 1) and a combination of hepatic 
artery thrombosis and recurrent HCV (n = 1). The causes of 
graft failure included patient death (with functioning graft; n = 
3), primary dysfunction without (n = I) or with patient death 
(n = 3), and liver allograft failure from cholestatic hepatitis 
(n = I) or a combination of hepatic artery thrombosis and re-
current HCV (n = 1). None of the allografts failed primarily 
from either AR or CR. 
Biopsy Timing and Diagnoses 
There were a total of 179 biopsies included in this study. 
The timing of the biopsies and the number of biopsies per pa-
tient are shown in Table 3. In total, grade mild AR or greater 
was diagnosed on 45 of 179 (25%) biopsies from 23 of 48 
(48%) patients (Table 4). The mean and median time to first 
onset of AR was 107 and 83 days, respectively, with a range of 
7 to 329 days. Early CR was diagnosed on 17 of 179 (9.5%) 
biopsies from 6 of 48 (12.5%) patients. The mean and median 
times until the first onset of early CR were 302 and 300 days, 
respectively, with a range of 170 to 413 days. None of the pa-
tients developed late CR. 8,12 Acute and/or chronic hepatitis 
was diagnosed on 86 of 179 (48%) biopsies from 31 of 48 
(65%) patients. The mean and median times until the first onset 
of recurrent HCV were 115 and 123 days, respectively, with a 
range of 22 to 315 days, 
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TABLE 3. Number and Timing of Liver Allograft Biopsies 
Obtained to Determine the Cause of Allograft Dysfunction 
No. % 
Biopsies/person 
I II 22.9 
2 8 16.7 
3 to 20.8 
4 6 12.5 
5-12 13 27.1 
Biopsies/time period 
0-7 days 12 6.7 
8-30 days 40 22.3 
31-60 days 16 8.9 
61-90 days II 6.1 
90-180 days 50 27.9 
181-365 days 37 20.7 
>365 days 13 7.3 
Correlation of Histopathologic Diagnoses With 
Liver Injury Test Profile 
Correlation of the histopathologic diagnosis with the 
liver injury test profile is shown in Table 5. Patients with a 
primary diagnosis of AR alone showed significantly lower se-
rum aspartate aminotransferase (AST) and ,),-glutamyl trans-
peptidase (GGTP) levels than patients with a primary diagno-
sis of AR and a secondary diagnosis of recurrent HCV. This is 
likely attributable to the more restrictive criteria used for a pri-
mary diagnosis of AR in the context of recurrent HCV. Con-
versely, however, there was no significant difference in the 
liver injury test profile in patients with a primary diagnosis of 
recurrent HCV alone versus those with a primary diagnosis of 
recurrent HCV and a secondary diagnosis of AR (Table 5). 
TABLE 4, Timing of First Onset of AR and CR and Recurrent 
HCV in the Study Population 
Time to first AR (days) 
Mean (SO) 
Median 
Range 
Time to first CR (days) 
Mean (SO) 
Median 
Range 
Time to recurrent Hey (days) 
Mean (SO) 
Median 
Range 
106.6 (109.8) 
83.0 
7-329 
302.3 (80.8) 
300 
170-413 
114.6 (58.5) 
123.0 
22-315 
AR, acute rejection; CR, chronic rejection; SO, standard deviation. 
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TABLE 5. Correlation of Liver Injury Test With 
Histopathologic Diagnoses 
Primary Other 
Diagnosis Diagnoses AST GGTP TB 
AR(n~II) HCY- Mean 222.1 232.5 7.0 
SO 203.0 137.9 6.0 
Median 110.0 181.5 4.7 
AR(n~ 19) HCY+ Mean 497.7 738.1 5.0 
SO 464.2 520.0 4.3 
Median 270.0 589.0 5.0 
P value 0.049 0.001 0.39 
HCY (n =42) AR- Mean 184.1 519.4 4.5 
SO 143.5 578.6 5.4 
Median 163.0 395.0 2.0 
HCY (n = 7) AR+ Mean 178.2 632.0 2.6 
SO 116.8 374.2 2.4 
Median 149.0 774.5 1.0 
P value 0.9 0.4 0.4 
HCV (n = 39) AR-/CR- Mean 186.2 416.7 4.2 
SO 145.7 453.1 5.3 
Median 154.5 287.0 1.7 
CR (any position) (n = 17) HCV +/- Mean 335.4 558.4 11.2 
SO 324.5 253.6 5.0 
Median 154.0 513.5 12.8 
P value 0.4 0.04 0.0004 
AR, acute rejection; CR, chronic rejection; HCV, hepatitis C virus hepa-
titis: TB. lotal bilirubin: +, present: -. absent. 
A diagnosis of CR, regardless of ranking, was associated 
with significantly higher GGTP and total bilirubin levels com-
pared with patients with HCV alone. This difference is attrib-
utable to the more diffuse bile duct damage and senescence 
seen in CR,26 which is not part ofthe histopathologic spectrum 
ofHCValone. 
Examples of Correct Identification and 
Treatment of Rejection and 
Recurrent Hepatitis 
Two predominant histopathologic patterns comprised an 
"AR profile" in the context ofrecurrent HCV: I) portal inflam-
mation with bile duct damage involving a majority of the portal 
tracts; and/or 2) peri venular mononuclear inflammation in-
volving a majority of central veins. The latter finding was as-
sociated with perivenular hepatocyte necrosis and dropout 
with or without portal inflammation. Early CR was recognized 
by senescence changes involving a majority of the bile ducts,z6 
A representative example of each AR profile and one for re-
current HCV are described below. 
The clinical course of the first patient, a 54-year-old 
man, is represented graphically in Figure I. A protocol 
preweaning biopsy obtained 109 days after transplantation 
showed recurrent HCV alone, characterized by mild portal in-
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flammation that was focally arranged into nodular aggregates, 
mild focal interface activity, and mild steatosis. No bile duct 
damage or perivenular inflammation was seen and liver injury 
tests were minimally abnormal, so weaning from immunosup-
pression began (Fig. 2A). Fifty days later (postoperative day 
206), elevated liver injury tests prompted a repeat biopsy that 
showed moderate to severe AR (Figs. 2B, C), characterized by 
moderate portal inflammation with prominent bile duct dam-
age involving virtually all of the bile ducts. The patient was 
initially treated with a pulse of corticosteroids. A follow-up 
biopsy obtained 11 days later (day 217) showed partial resolu-
tion of the portal inflammation, but senescence changes ap-
peared in a majority of the bile ducts signaling the onset of 
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FIGURE 1. Dose and blood levels of baseline immunosuppres-
sion (top panel), HCV RNA levels and anti-viral therapy (sec-
ond panel from top), liver injury test (third panel from top), 
and timing of biopsies and augmentation of immunosuppres-
sion (bottom panel) in a patient correctly diagnosed as devel-
oping AR after weaning of immunosuppression. Note the dra-
matic increase in total bilirubin (Tbili), aspartate aminotrans-
ferase (AST), and -y-glutamyl transpeptidase (GGTP) after 
weaning of immunosuppression. A correct histopathologic 
diagnosis (see Fig. 2) of rejection prompted return to daily 
tacrolimus therapy and treatment with corticosteroids, which 
eventually resulted in resolution of liver injury tests abnormali· 
ties. Despite the low levels of HCV RNA, the PCR for HCV was 
positive. 
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FIGURE 2. Appearance of liver allograft biopsies from the pa-
tient whose clinical course is shown in Figure 1. A: A protocol 
preweaning liver biopsy obtained on day 109 showed mild 
chronic portal and spotty hepatocyte necrosis but without bile 
duct damage or portal or central venulitis. These findings 
prompted a diagnosis of recurrent HCV alone. Band C: An-
other biopsy was obtained after weaning of immunosuppres-
sion on day 206 because of markedly increased liver injury test 
(see Fig. 1). Note the prominent mononuclear portal inflam-
mation and prominent bile duct damage (arrows), which in-
volved the majority of the ducts. Attention is drawn to the bile 
ducts (C; arrows), which are shown at higher magnification on 
the right side of (C). D: A follow-up biopsy obtained 11 days 
later (day 217) after treatment with increased immunosup-
pression showed partial resolution of the portal inflammation, 
but a majority of the bile duct showed senescence-related 
changes, prompting a diagnosis of early CR (arrows). An ex-
ample of an affected bile duct (arrow) is shown at higher mag-
nification in the right panel of D. A return to daily tacrolimus 
and maintenance corticosteroids eventually resulted in near 
normalization of the liver injury tests. 
early CR (Fig. 2D). Re-institution of daily tacrolimus and 
maintenance corticosteroid therapy eventually lowered the 
markedly elevated liver injury test (total serum bilirubin 
peaked >50 mg/dL) to near-normal levels without a concomi-
tant increase in HCY RNA levels. 
The clinical course of the second patient, a 52-year-old 
woman, is represented graphically in Figure 3. A pre weaning 
biopsy obtained about 3.5 months after transplantation showed 
low-grade pcrivenular inflammation, which was not treated 
with increased immunosuppression because of normal liver in-
jury tests. There was minimal histopathologic evidence of re-
current HCY at this time. Approximately 3.5 months after the 
start of weaning, a sharp rise of AST and GGTP prompted the 
liver biopsy shown in Figure 4. Mild portal inflammation with 
minimal interface activity and mild focal bile duct damage 
combined with prominent peri venular inflammation and hepa-
tocyte dropout resulted in focal central-to-central bridging ne-
© 2004 Lippincott Williams & Wilkins 
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crosis. A primary histopathologic diagnosis of mild acute cel-
lular rejection prompted treatment with 2 pulses of corticoste-
roids, followed by a single injection of Alemtuzumab. This led 
to a prompt return ofliver injury tests to normal levels, without 
a significant rise in the HCY RNA levels. 
The clinical course of a 45-year-old man successfully 
recognized and treated as suffering from recurrent HCY alone 
after withdrawal from immunosuppression is shown in Figure 
5. This patient first had evidence of recurrent HCV in a biopsy 
obtained on day 150 after transplantation, manifest as primar-
ily as spotty acidophilic necrosis of hepatocytes with minimal 
portal inflammation. This was followed by biopsies on days 
232,296, and 388, all of which showed changes characteristic 
of recurrent chronic HCY including variable mononuclear por-
tal inflammation, interface activity, lobular disarray, and 
spotty hepatocyte necrosis (Fig. 6). No significant bile duct 
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FIGURE 3. Clinical course of a patient who developed AR after 
being weaned from immunosuppression. Approximately 5 
months after transplantation (top panel) and several weeks 
after a protocol biopsy that showed minimal focal perivenular 
inflammation, the immunosuppression was lowered (top 
panel). Approximately 3 months after spaced dosing of tacro-
limus and low whole blood levels of tacrolimus <5 nglmL (top 
panel), the patient developed elevations of the AST and GGTP 
to levels >600 lUlL (third panel from top). This prompted a 
repeat liver biopsy shown in Figure 4. Note the low levels of 
HCV RNA during the course. 
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FIGURE 4. Liver biopsy from the patient whose clinical course 
is shown in Figure 3. It was obtained 8.5 months after trans-
plantation and 3 months after weaning of immunosuppres-
sion. The most striking changes were perivenular inflamma-
tion, centrilobular hepatocyte dropout, and early perivenular 
fibrosis, which prompted a diagnosis of mild AR. A: Note that 
the inflammation is concentrated around the central veins 
(CV). Band C: Note the mild portal tract CPT) inflammation 
with focal mild bile duct damage but prominent perivenular 
inflammation. D: Higher magnification of an involved central 
vein showing the prominent perivenular inflammation consist-
ing of lymphocytes and plasma cells. There is also red blood 
cell congestion, hepatocyte dropout, and early perivenular fi-
brosis. 
damage or peri venular inflammation was seen in any of the 
biopsies. While being maintained on low levels of baseline im-
munosuppression (Fig. 5), the patient experienced fluctuating 
liver injury tests and HeV RNA levels over 6.5 months until 
treatment with a combination of interferon and ribavirin 
caused a dramatic lowering of the liver injury tests. 
Identification and Explanation of Errors 
We identified one major error and two minor errors in 
the pathology diagnoses. The major error occurred in a 36-
year-old man who was subjected to an initial biopsy on day 39 
because of elevated AST levels. The biopsy showed changes 
consistent with recurrent HeV alone, manifest as very mild 
chronic portal inflammation and spotty acidophilic necrosis of 
hepatocytes without bile duct damage or venulitis. Weaning of 
immunosuppression resulted in an increase in liver injury tests 
(Fig. 7), which in tum, prompted a repeat biopsy on day 82. It 
showed markedly increased portal inflammation. Bile duct 
damage was present but involved a minority of the portal 
tracts. There was also prominent lobular disarray, a type II due-
tular reaction, and hepatocyte necrosis. A mistaken primary 
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diagnosis of mild AR with a secondary diagnosis of recurrent 
HeV (Fig. 8) prompted re-institution of daily tacrolimus 
therapy and a short cycle of steroids. 
Treatment with more immunosuppression caused an im-
mediate worsening of liver injury tests. Another follow-up bi-
opsy obtained almost a week later (day 88) showed noticeably 
less portal inflammation but centrilobular hepatocyte swelling 
and hepatocanalicular cholestasis appeared, clear indicators of 
the development of cholestatic hepatitis (Fig. 9). Recognition 
of the mistake in this follow-up biopsy prompted a lowering of 
immunosuppression; the patient was also started on pegylated 
interferon and ribavirin. The anti-viral therapy resulted in dra-
matic lowering of the liver injury tests and lower viral loads 
(Fig. 7). An additional follow-up biopsy obtained on day 100 
showed changes of recurrent Hev alone. 
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FIGURE S. Clinical course of a patient correctly recognized and 
treated as recurrent Hev alone. Note that weaning from im-
munosuppression began approximately 4 months after trans-
plantation (top panel) after a protocol biopsy (bottom panel) 
showed changes of recurrent HCV alone. Marked fluctuation 
of liver injury tests after weaning from immunosuppression 
prompted several liver allograft biopsies, all of which showed 
changes of recurrent HCV alone (see Fig. 6). Consequently, the 
patient was treated with a combination of interferon and riba-
virin (panel second from top), which eventually resulted in a 
normalization of liver injury test (middle panel). 
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FIGURE 6. Liver allograft biopsies obtained from the patient 
whose clinical course is shown in Figure 5. A: The protocol 
preweaning biopsy obtained approximately 4 months after 
transplantation showed mild mononuclear portal inflamma-
tion, mild interface activity, and spotty acidophilic necrosis of 
hepatocytes. There was no evidence of bile duct damage or 
perivenular inflammation. The inset in the lower left corner 
shows the portal tract marked by the arrow at higher magni-
fication. B: A repeat biopsy obtained about 6 months after 
weaning, during the peak of liver injury test abnormalities also 
showed changes of recurrent HCV alone. Note the mild mono-
nuclear portal inflammation arranged into a small nodular ag-
gregates (*), intact bile ducts (arrows), and type II ductular 
reaction at the interface zone (brace). None of the biopsies 
from the patient showed any changes of AR or CR. 
A minor diagnostic error occurred approximately 10 
months after transplantation and 6 months after weaning of 
immunosuppression. A secondary diagnosis of mild AR re-
sulted in treatment with a single bolus of steroids, which in tum 
resulted in a slight worsening of liver injury tests. Follow-up 
biopsies 1,4, and 6 months later showed predominantly or only 
recurrent HCV. Rejection activity, if present at all in any of 
these biopsies, was of indeterminate severity. 
The final minor error occurred during the interpretation 
of a protocol biopsy obtained 4 months after transplantation, 
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just before beginning weaning of immunosuppression. A sec-
ondary diagnosis of mild AR was ignored by the clinicians and 
weaning proceeded without any worsening of the near-normal 
liver injury tests. 
A total of 105 of the 179 (59%) biopsies were obtained 
more than 30 days after transplantation and therefore were 
considered "at risk" for confusing AR with recurrent H CV. All 
errors were similar: AR was overdiagnosed in thc context of 
recurrent HCV. The positive predictive values of rejection and 
hepatitis diagnoses were 91 % and 100%, respectively. 
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FIGURE 7. Clinical course of the patient whose liver allograft 
biopsy was misinterpreted as primarily AR, when in retrospect, 
the changes represented aggressive recurrent HCV. Weaning 
from immunosuppression (top panel) began several months 
after transplantation because a preweaning biopsy obtained 
on day 39 showed changes of recurrent HCV alone. By day 82, 
the liver injury tests as well as total serum bilirubin increased 
dramatically (third panel from top). This prompted a repeat 
liver biopsy, shown in Figure 8, which was misinterpreted as 
showing primarily AR with a secondary diagnOSis of recurrent 
HCV. Return to daily tacrolimus therapy (top panel) and treat-
ment with a pulse of corticosteroids (bottom panel) resulted in 
a further worsening of liver injury tests (third panel from top). 
A repeat biopsy 6 days later (Fig. 9; day 88) showed features of 
cholestatic hepatitis, a diagnosis that led to a decrease in im-
munosuppression and treatment with interferon and ribavirin. 
Eventually the anti-viral therapy led to a marked improvement 
in liver injury tests and a dramatic fall in HCV RNA levels (sec-
ond panel from top).' 
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FIGURE 8, Liver allograft biopsy misinterpreted as showing 
primarily AR with a secondary diagnosis of recurrent HeV. The 
clinical course of this patient is shown in Figure 7. A: Note the 
prominent portal tract (PT) inflammation. B: In this portal 
tract, there is mild to moderate mononuclear portal inflamma-
tion and a ductular reaction at the interface zone, but minimal 
inflammatory bile duct damage (arrow). C: In contrast, other 
portal tracts from the same biopsy showed easily identifiable 
lymphocytic infiltration and damage of the small bile ducts 
(arrows). The prevalence of inflammatory bile duct damage 
was greater than is usually seen with HeV alone, but in retro-
spect, did not involve a majority of the bile ducts. 
Retrospective Analysis of Errors and How They 
Might Be Avoided 
Tn our opinion, the most serious error occurred because 
of anxiety over the uncertainty about the impact of conflicting 
influences of the treatment protocol on the biologic and histo-
pathologic manifestations of recurrent HCV and rejection. It 
was reasoned that depleting antibody pretreatment might raise 
viral levels 11 early after transplantation. Subsequent weaning 
of immunosuppression had the potential to "re-arm" the im-
mune system that could cause either severe hepatitis or severe 
rejection. 13•16 In retrospect, the major mistake would have 
probably not occurred if we had strictly adhered to our original 
histopathologic criteria and ignored the low blood levels of 
immunosuppression. In addition, retrospective analysis of the 
clinical course of this patient showed that HCV RNA levels 
were >50 million TU/mL at the time of the misinterpreted bi-
opsy. Thereafter, an attempt was made to include routine 
monitoring of HCV RNA levels in patient management, but 
values were routinely not available until recently during prepa-
ration of this manuscript. 
Correlation of Histopathology Diagnosis With 
HCV RNA Levels 
Serial plasma HCV RNA levels according to the histo-
pathologic diagnosis were plotted versus time after transplan-
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tation (Fig. 10). In general, HCV RNA levels were greatest 
during the first 6 months after transplantation, although the 
results varied among patients and values fluctuated signifi-
cantly over time in individual patients. 
Quantitative HCV RNA levels near the time of biopsy 
were available for 10 of 14 patients with histopathologic diag-
noses of moderate or severe AR or early CR (Fig. 10). All of 
the episodes in these 10 recipients occurred more than 100 
days after transplantation, and all but one of these patients, 
who had titers of 11.8 million TUlmL, showed HCV RNA lev-
els of <10 million IU/mL at the time of the rejection diagnosis. 
Hev RNA levels were not available near the time of the biop-
sies in the 4 remaining patients, all of whom experienced mod-
erate or severe AR or early CR less than 30 days after trans-
plantation. The two patients who developed cholestatic HCY 
showed HCV RNA levels of>50 million IU/mL at the time of 
diagnosis. There was a wide range of HCV levels (0-30 mil-
lion IU/mL) in recipients with a primary histopathologic diag-
nosis of recurrent HCV (Fig. 10). 
Analysis of Risk Factors for the Development 
of Acute and Chronic Rejection 
Six of the II HCV-positive recipients simultaneously 
maintained on low immunosuppression and treated with a 
combination of interferon and ribavirin developed significant 
rejection, defined as moderate or severe AR or CR. The re-
maining 5 of II patients treated with a combination of inter-
feron and ribavirin, 2 other recipients treated with interferon 
alone, and a third patient treated with ribavirin alone did not 
develop significant rejection. 
FIGURE 9. Follow-up biopsy from the patient whose clinical 
course and previous liver allograft biopsy are shown in Figures 
7 and 8, respectively. A and B: Treatment with increased im-
munosuppression caused a dramatic decrease of the portal 
inflammation compared with the biopsy shown in Figure 8; it 
also caused marked hepatocyte swelling, hepatocanalicular 
cholestasis (left side of B), and a prominent ductular reaction at 
the interface zone (right side of B), all of which are character-
istic features of cholestatic hepatitis. HeV RNA levels measured 
retrospectively from a sample obtained near the time of this 
biopsy were >50 million IU/mL (PT, portal tract), 
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FIGURE 10. Correlation between quantitative HCV RNA levels 
and primary histopathologic diagnosis plotted against time 
after transplantation. The HCV RNA levels were obtained 
within a window from 14 days before until 3 days after the 
corresponding biopsy. Note that the highest levels of HCV 
RNA are detected during the first 6 months after transplanta-
tion, and thereafter levels generally decrease. In addition, HCV 
RNA levels> 10 million IU/mL are almost invariably associated 
with a histopathologic diagnosis of recurrent HCV alone, and 
very high levels are seen in association with cholestatic hepa-
titis. Conversely, moderate and severe AR, and especially early 
CR, almost invariably shows relatively low HCV RNA levels. The 
point corresponding to the major mistake was not included in 
this graph. 
Univariate models were first examined for predictors of 
AR and/or CR. Those parameters that reached a significance 
level of 0.10 were then used in multivariable models. Param-
eters that were considered for these models included basic do-
nor and recipient characteristics such as age, race, and gender. 
Other variables included were cold ischemia time, pretrans-
plantation crossmatch, antibody pretreatment, and posttrans-
plantation anti-viral therapy. Only moderate or severe AR was 
used in the analysis for AR. 
Predictors of AR in this patient population include fe-
male recipients (P = 0.04; hazard ratio [HR] = 4.0) and pre-
treatment with Thymoglobulin versus CamPath pretreatment 
(P = 0.05 HR = 8.0). Since older donor livers tended to develop 
CR sooner than younger donors, the CR model and the AR or 
CR model was adjusted for donor age. Treatment with inter-
feron and ribavirin appeared to be a predictor ofCR (P = 0.03; 
hazard ratio = 12.6); AR was weakly predictive of CR (P = 
0.11; HR = 2.8), probably because of the small number ofpa-
tients that experienced CR. Predictors of either AR or CR in-
cluded female recipients (P = 0.02; HR = 4.7), pretreatment 
with Thymoglobulin (P = 0.08; HR =6.6), and treatment with 
interferon and ribavirin (P = 0.09; HR 4.0). Indeed, 13 of 14 
patients who developed moderate or severe AR or early CR 
received Thymoglobulin pretreatment and of these, 4 of 6 who 
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went on to develop early CR were also treated with anti-viral 
therapy for recurrent HCV . 
DISCUSSION 
In conventionally treated liver allograft recipients, AR 
usually occurs during the first month after transplantation; re-
current HCV usually first appears more than I month after 
transplantation. Thus, timing alone can be used to determine 
the cause of new onset liver allograft dysfunction. For patients 
enrolled in this protocol, the mean time to first onset of AR was 
107 days, which significantly overlapped with first onset of 
recurrent HCV at 115 days. Consequently, distinguishing be-
tween rejection and recurrent HCV could not be based solely 
on time since transplantation and was especially troubling and 
particularly reliant on biopsy evaluation. The unusually long 
interval until the first onset of AR 15,40 is likely attributable to 
the protocol: pretransplantation immunodepletion followed by 
weaning of immunosuppression. Regardless, this study pro-
spectively documents that interpretation of liver allograft bi-
opsies can be used to quickly (6-7 hours) and accurately dis-
tinguish recurrent HCV from AR and CR, even under chal-
lenging conditions. 
We found that the most problematic biopsies are a subset 
of those showing changes primarily of recurrent HCV. The 
troubling subset also shows bile duct damage or peri venular 
inflammation that is more prevalent than usually encountered 
with HCV alone, but stiJJ involving :s:50% of bile ducts or 
central veins, respectively. In such cases, it is our opinion that 
AR should be considered mild at most, and as a secondary 
diagnosis. These patients should not be treated with additional 
immunosuppression. Instead, they should be closely followed 
and subjected to re-biopsy if liver injury tests continue to rise. 
Increased immunosuppression should be considered as a 
treatment option only when rejection is judged to be the pri-
mary insult. This condition is met when obvious bile duct dam-
age or perivenular inflammation and hepatocyte dropout 
clearly involves most ofthe bile ducts or central veins, respec-
tively. In our experience, AR-related findings should be obvi-
ous for biopsies in which AR is the primary insult. Such biop-
sies are usually graded as moderate or severe AR according to 
the Banff schema (1997) and usually associated with higher 
liver tests than HCV alone or mild rejection alone,15 as con-
firmed in this study. 
The above algorithm is recommended because liver al-
lografts are very "forgiving" compared with other allografts: 
they can recover from most rejection-related insults and repair 
without fibrosis. 15 Conversely, unnecessary additional immu-
nosuppression can significantly worsen hepatitis or even trig-
ger fibrosing cholestatic hepatitis, and such patients usually 
suffer significant and often permanent liver damage from se-
vere recurrent HCV. Furthermore, all of the mistakes in this 
series and in most other reports 1.19.25 were in the same direc-
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lion; too great an emphasis was placed on mild AR findings in 
the context of recurrent HCY. 
Although this study was carried out under a specific im-
munosuppressive protocol, it is our opinion that histopatholog-
ic findings and recommendations are generically applicable to 
other liver allograft recipients subjected to different ap-
proaches to immunosuppression. This contention is supported 
by the following observations: 1) the algorithm used in this 
study to distinguish between viral hepatitis and rejection was 
developed long ago in patients under a different immunosup-
pression protocoI 13.16,3 \ 2) even with low immunosuppres-
sion and the increased risk of rejection, we still overestimated 
the risk of AR; and 3) the same tendency to overdiagnose AR 
in the context of recurrent HCY occurs in liver allograft recipi-
ents treated with different approaches to immunosuppression. 
This statement is particularly true if the histopathologic find-
ings are not clear_cut. 1,19,2S 
Correlation of the biopsy findings with the clinical 
course, including an examination of serum HCY titers, serial 
liver injury tests in relation to immunosuppression, weekly 
meetings to discuss and collate all of this information, and im-
portantly, insistence by the clinicians that there be unequivocal 
histopathologic evidence of significant rejection before giving 
any additional immunosuppression offered the best approach 
to optimal management. Real-time availability of graphical 
representations of the clinical course (ie, pertinent clinical, 
biochemical, and treatment data) made possible by the EDIT 
software greatly facilitated the entire process and reporting of 
the results. 
Serial HCY RNA levels provided information useful for 
the histopathologic interpretation, but caution is urged against 
placing too much emphasis on HCY levels alone. There is a 
wide variation of HCY levels among patients, the values fluc-
tuate significantly over time in individual patients, and there is 
considerable overlap in patients with different histopathologic 
diagnoses, particularly early after transplantation. Neverthe-
less, similar to other studies, the highest HCY RNA values 
were observed early after transplantation and during episodes 
ofcholestatic HCV.6,28,42 In contrast, all but one of the patients 
with late onset (>60 days) moderate or severe AR or CR 
showed HCY RNA levels <10 million IU/mL and most 
showed levels <2 million IU/mL. Thus, a diagnosis of moder-
ate or severe AR or CR occurring more than 60 days after 
transplantation should be made with extreme caution in a pa-
tient with HCY RNA levels of> 1 0 million IU/mL. Similar 
results were obtained by Gottschlich et al 19 who showed that 
higher HCY RNA levels were more frequently associated with 
an unequivocal diagnosis of recurrent HCY. 
Relatively high HCY RNA levels during the first 6 
months followed by a return to relatively low levels thereafter 
is most probably related to antibody pretreatment, disruption 
by transplantation of the previously established equilibrium 
between the host and virus, and later weaning of immunosup-
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pression.21 ,22,24,41 The unusual responsiveness ofHCY levels 
and liver injury tests to anti-viral therapy in the weaning 
patients (unpublished observation) is likely attributable to 
lower overall immunosuppression, and in particular, the in-
frequent and sparing use of pulse or recycle corticosteroid 
therapy.6,9,18,30,42 Our hope is that HCY might be more easily 
controlled or eliminated after transplantation, but using this 
protocol in HCY-positive recipients requires very close patient 
monitoring. We have already observed an increased incidence 
of early CR, IS but there have been no graft failures from either 
AR or CR. In addition, most of the cases of early CR occurred 
early in the protocol and have recovered to near-normal liver 
injury tests with appropriate treatment. We are also aware that 
assessment of efficacy for both rejection and HCY will require 
longer-term follow-up because "re-arming" the immune sys-
tem after immunodepletion has the potential to accelerate liver 
damage from recurrent HCy.7,32 
The relatively low «10 million IU/mL) HCY RNA lev-
els and a paucity of hepatitis histopathologic findings during 
moderate or severe AR and CR versus high HCY RNA levels 
in cholestatic hepatitis and a complete absence of rejection-
related histopathologic findings are interesting observations. 
Significant AR and CR in liver allografts have been associated 
with a strong T H I-type hepatic microenvironment and cyto-
toxic T -lymphocyte response.2°,34,38,42 These effector mecha-
nisms also are crucial determinants of HCY clearance and 
HCY-induced liver damage. IO,21,22,41 In contrast, cholestatic 
HCY has been associated with high viral levels and a strong 
T H2-type intrahepatic microenvironment42 and hepatic tolero-
genesis.29 Consequently, rejection and HCY clearance appear 
to be closely linked because all of the risk factors for signi fi-
cant rejection in this study (pretreatment with Thymoglobulin 
vs. CamPath, low-immunosuppression and anti-viral therapy 
including interferon) simultaneously enhanced viral clearance. 
It is tempting to speculate about the role that hepatic den-
dritic cells might play in the outcome because of their ability to 
initiate and perpetuate immune responses. HCY interacts with 
DC-SIGN, 17,39 a receptor on dendritic cells that has the capac-
ity to regulate their maturation and promote T H2-type micro-
environment.2,39 Since dendritic cells are classically associ-
ated with rejection 14 and HCY appears to diminish their allo-
stimulatory capacity,4,23 HCY may be particularly suited for 
co-survival of the virus as well as the liver recipient. Early 
immunosuppression needed to prevent rejection enhances 
HCY replication, which in turn helps to subvert the allo-
response. Thus, the virus protects itself from clearance and the 
allograft from rejection. Conversely, while weaning ofimmu-
nosuppression with addition of interferon may re-arm the im-
mune system and promote HCY clearance, it also could in-
crease the risk of rejection, and both rejection and the immune 
response leading to HCY clearance can significantly damage 
the liver. It seems, therefore, that the optimal approach for the 
treatment of HCY-positive liver allograft recipients would be 
© 2004 Lippincott Williams & Wilkins 
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similar to hepatitis B. Agents that directly interfere with viral 
replication are needed. 
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